Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Design and Production an Effective Bispecific Tandem Chimeric Antigen Receptor on T Cells Against Cd123 and Folate Receptor ß Towards B-Acute Myeloid Leukaemia Blasts Publisher



Ghamari A1 ; Pakzad P2 ; Majd A1 ; Ebrahimi M3 ; Hamidieh AA4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Cellular and Molecular Biology, Faculty of Biological Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran
  2. 2. Department of Microbiology, Faculty of Biological Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran
  3. 3. Department of Stem Cells and Developmental Biology, Cell Science Research Centre, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
  4. 4. Pediatric Cell and Gene Therapy Research Center, Gene, Cell and Tissue Research Institute, Tehran University of Medical Sciences, P.O.Box: 1419733151, Tehran, Iran

Source: Cell Journal Published:2021


Abstract

Objective: The clinical studies of acute myeloid leukaemia (AML) revealed that antigen escaping variants cause cancer recurrence even after treatment with chimeric antigen receptor (CAR)-T cells that target a single tumour antigen. Due to the heterogeneous expression of antigens on leukaemia blasts, we hypothesized that a novel bispecific CAR, directed to the folate receptor beta (FRβ)-binding single-chain variable fragment (scFv) and an IL3α-binding receptor (CD123) that has more expression in AML blasts, can decrease CAR-T cell exhaustion and increase the efficacy of CAR-T cells to prevent antigen escaping and consequent recurrence of AML. Materials and Methods: In this experimental study, the survival, proliferation, and cytolysis of CAR-T cells remains suboptimal even with a costimulatory endodomain. Hence, we designed and constructed a tandem CAR that joins an FRβ and CD123 in the second generation retroviral vector to generate a bispecific tandem CAR (TanCAR-T cell). Results: TanCAR FRβ-CD123 T cells showed distinct binding to FRβ or CD123 expressing cells. They could lyse the leukaemia cell lines (66.1 ± 11%) comparable to the single CAR-T cells against these determinants. TanCAR FRβCD123 T cells simultaneously engaged FRβ and CD123, which promoted T cell activation in targeting and lysis of the examined leukaemia cell lines. TanCAR-T cell significantly induced interferon gamma (IFNγ) and interleukin 2 (IL-2) production more than single CAR-T cells, which produced a synergistic enhancement of TanCAR FRβ-CD123 T cell function when dual antigens faced simultaneously. Conclusion: Dual-specific TanCAR FRβ-CD123 T cells showed therapeutic potential to improve AML control by co-engaging FRβ and CD123 molecules in a robust, divalent immune system. This strategy may be a useful therapeutic approach in patients with relapsed B-cell malignancies. © 2021 Royan Institute (ACECR). All rights reserved.
Related Docs
View other Related Docs
1. Car T Cell Therapy in Solid Tumors; With an Extensive Focus on Obstacles and Strategies to Overcome the Challenges, International Immunopharmacology (2021)
2. Car-T Cells: Early Successes in Blood Cancer and Challenges in Solid Tumors, Acta Pharmaceutica Sinica B (2021)
3. T Cell Engineered With a Novel Nanobody-Based Chimeric Antigen Receptor Against Vegfr2 As a Candidate for Tumor Immunotherapy, IUBMB Life (2019)
4. Programmable and Multi-Targeted Cars: A New Breakthrough in Cancer Car-T Cell Therapy, Clinical and Translational Oncology (2021)
5. Chimeric Antigen Receptor -T Cell Therapy: Applications and Challenges in Treatment of Allergy and Asthma, Biomedicine and Pharmacotherapy (2020)
6. Novel Car T Therapy Is a Ray of Hope in the Treatment of Seriously Ill Aml Patients, Stem Cell Research and Therapy (2021)
7. Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications, Frontiers in Immunology (2017)
8. Remote Controlling of Car-T Cells and Toxicity Management: Molecular Switches and Next Generation Cars, Translational Oncology (2021)
Experts (# of related papers)
View all Related Experts
Hamid Reza Mirzaei (7)
Nima Rezaei (7)
Other Related Docs
9. Car-Nk Cells for Haematological Cancers, Best Practice and Research: Clinical Haematology (2025)
10. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells, Frontiers in Immunology (2018)
11. Cancer Stem Cell-Targeted Chimeric Antigen Receptor (Car)-T Cell Therapy: Challenges and Prospects, Acta Pharmaceutica Sinica B (2021)
12. Therapeutic Roles of Car T Cells in Infectious Diseases: Clinical Lessons Learnt From Cancer, Reviews in Medical Virology (2022)
13. A Metabolic Switch to Memory Car T Cells: Implications for Cancer Treatment, Cancer Letters (2021)
14. Hurdles in Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
15. Solid Tumors Challenges and New Insights of Car T Cell Engineering, Stem Cell Reviews and Reports (2019)
16. The Current Landscape of Car T-Cell Therapy for Solid Tumors: Mechanisms, Research Progress, Challenges, and Counterstrategies, Frontiers in Immunology (2023)
17. Neurological Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy, Expert Review of Clinical Immunology (2023)
18. Predictive and Therapeutic Biomarkers in Chimeric Antigen Receptor T-Cell Therapy: A Clinical Perspective, Journal of Cellular Physiology (2019)
19. Car-Engineered Nk Cells Versus Car T Cells in Treatment of Glioblastoma; Strength and Flaws, Journal of Neuro-Oncology (2025)
20. Antigenic Targets of Car T Cell Therapy. a Retrospective View on Clinical Trials, Experimental Cell Research (2018)
21. Resistance to Immunotherapy in Human Malignancies: Mechanisms, Research Progresses, Challenges, and Opportunities, Journal of Cellular Physiology (2022)
22. The Efficacy and Applicability of Chimeric Antigen Receptor (Car) T Cell-Based Regimens for Primary Bone Tumors: A Comprehensive Review of Current Evidence, Journal of Bone Oncology (2024)
23. Car-Engineered Nk Cells; a Promising Therapeutic Option for Treatment of Hematological Malignancies, Stem Cell Research and Therapy (2021)
24. Natural Killer Cells and Acute Myeloid Leukemia: Promises and Challenges, Cancer Immunology# Immunotherapy (2022)
25. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
26. Genetic Modification of Cytokine Signaling to Enhance Efficacy of Car T Cell Therapy in Solid Tumors, Frontiers in Immunology (2021)
27. Chimeric Antigen Receptor T-Cell Therapy for Breast Cancer, Future Oncology (2021)
28. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)
29. Proposing a Tandem And-Gate Car T Cell Targeting Glioblastoma Multiforme, Medical Hypotheses (2020)
30. Monoclonal Antibodies for the Treatment of Acute Lymphocytic Leukemia: A Literature Review, Human Antibodies (2022)
31. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
32. Applications of Single-Cell Omics for Chimeric Antigen Receptor T Cell Therapy, Immunology (2024)
33. Genetically Modified Immune Cells Targeting Tumor Antigens, Pharmacology and Therapeutics (2020)
34. Production of Car T-Cells by Gmp-Grade Lentiviral Vectors: Latest Advances and Future Prospects, Critical Reviews in Clinical Laboratory Sciences (2019)
35. Car-Modified T-Cell Therapy for Cancer: An Updated Review, Artificial Cells# Nanomedicine and Biotechnology (2016)
36. Cancer Immunotherapy: Diverse Approaches and Obstacles, Current Pharmaceutical Design (2022)